ABCB1 and cancer: This is particularly relevant in canine cancer therapeutics, where there is a narrow therapeutic index, and reported case studies include dogs with ABCB-1 mutations undergoing chemotherapy for lymphoma which experienced more severe adverse effects than expected to P-glycoprotein substrates vincristine and doxorubicin (73, 74).